Friday, June 17, 2011

All Juice, No Seeds

For now, researchers and consumers can only assume that when presented with a full pipeline of new drugs and better data on the safety, efficacy and public acceptability of male contraceptives, pharmaceutical companies will eventually see an opportunity for their profit margins. The hope is, "If you make it, they will come," NIH's Blithe says.

Yes. Yes, I suppose they will. Not that they weren't already. In fact, that's kind of the problem, isn't it?

That's from an article in Scientific American, talking about trying to develop a new male contraceptive. Scientific American. So, uh, I guess it's safe to say that pun was unintentional...?